Dr. Mas Takashima, the trial's principal investigator, is scheduled to present the findings on October 16 during the conference’s Top 5 Clinical Science session. The study, a randomized, double-blind, placebo-controlled trial, previously reported that the treatment met its primary safety endpoints without serious adverse events. Beyond safety, the data indicate durable improvements in smell function across secondary efficacy markers.

This selection highlights a significant shift in rhinology, as the field seeks viable pharmacological solutions for olfactory dysfunction—a condition currently lacking approved medical treatments. Rick Geoffrion, CEO of Cyrano Therapeutics, noted that the forum offers a critical venue to engage specialists on the potential of CYR-064. The ARS meeting runs from October 15 to 17, 2026, marking a key milestone for the Delray Beach-based company’s clinical development program.